GSK’s Nucala Gains Favorable Review Position from FDA for COPD Treatment
GSK plc revealed that the United States Food and Drug Administration (FDA) has begun the review process for data derived from the MATINEE study to potentially approve Nucala (mepolizumab) as an add-on maintenance therapy targeted at patients with eosinophilic chronic […]
GSK’s Nucala Gains Favorable Review Position from FDA for COPD Treatment Read More »